[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"infant-discomfort\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:infant-discomfort":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100652808","effects-of-goat-milk-formula-on-gastrointestinal-comfort-and-growth-in-infants-100652808",false,"NCT07778927","Effects of Goat Milk Formula on Gastrointestinal Comfort and Growth in Infants","A Multicenter, Randomized, Controlled Trial to Evaluate the Effects of Goat Milk Formula on Gastrointestinal Comfort, Behavioral Status, and Early Growth and Development in Infants","Inclusion Criteria:\n\n* Infants aged 0 to 5 months at enrollment\n* Full-term birth (gestational age ≥37 weeks)\n* Birth weight ≥2500 g\n* Infants with symptoms of gastrointestinal discomfort (e.g., abdominal distension, excessive crying, regurgitation, or feeding intolerance)\n* Parents or legal guardians able and willing to provide written informed consent and comply with study procedures\n\nExclusion Criteria:\n\n* Infants with known or suspected organic gastrointestinal diseases (e.g., congenital malformations, Hirschsprung disease)\n* History of severe perinatal complications or significant systemic diseases\n* Known or suspected cow's milk protein allergy or other food allergies\n* Use of antibiotics, probiotics, or other medications that may affect gastrointestinal function within 2 weeks prior to enrollment\n* Participation in another clinical study within the past 3 months\n* Any condition that, in the investigator's judgment, may interfere with study participation or outcome assessment For the reference cohort: healthy breastfed infants without significant gastrointestinal symptoms",true,"ALL","5 Months",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"NA","Infant gastrointestinal discomfort is common in early life and can affect feeding, sleep, and overall well-being. Goat milk formula, due to its unique protein composition and smaller fat globules, may be easier to digest and potentially improve gastrointestinal tolerance in infants.\n\nThis study is a multicenter, randomized, controlled trial designed to evaluate the effects of goat milk formula compared with standard cow milk formula in infants aged 0-5 months with gastrointestinal discomfort. The study will assess improvements in gastrointestinal symptoms, overall comfort, behavioral status, and early growth and development, as well as explore potential changes in gut microbiota and intestinal inflammation.",[27,28],"Functional Gastrointestinal Disorders (FGIDs)","Infant Discomfort","NOT_YET_RECRUITING","2026-08-20",{"date":32,"type":33},"2026-08-21","ACTUAL",{"date":35,"type":21},"2026-08-01",{"date":37,"type":21},"2027-12-31",{"name":39,"class":40},"Ruijin Hospital","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":54,"conditions":55,"keywords":60,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100630908","phase-2-dexmedetomidine-for-invasive-ventilation-in-the-neonate-100630908","NCT07493785","Dexmedetomidine for Invasive Ventilation In the NEOnate","Double Blind, Multicenter, Randomized, Controlled Trial of Dexmedetomidine vs Placebo in Premature Neonates Receiving Invasive Ventilation","Above mentioned age limits (0 -10 weeks) apply to postnatal age. Inclusion criteria apply to gestational age at birth and postmenstrual age (in weeks).\n\nInclusion Criteria:\n\n* Neonates with a gestational age at birth \\\u003C 32 weeks of gestation and corrected gestational age \\\u003C 32 weeks postmenstrual age\n* Invasively ventilated with an expected or effective duration of ventilation \\> 24 hours at inclusion\n* Under mechanical ventilation since less than 72 hours at inclusion\n* With parental consent\n* Affiliated to or benefiting from a social security system\n\nExclusion Criteria:\n\n* Previous inclusion in this trial\n* Participation in another trial including analgesics or sedatives\n* Ongoing palliative care\n* Administration of dexmedetomidine or another alpha-2 agonist in the 96 previous hours\n* Hemodynamic compromise defined as any of: poor perfusion (increased capillary refill time, oliguria); hypotension defined as a mean blood pressure in mm Hg \\\u003C postmenstrual age in weeks; ongoing inotropic treatment with dopamine or dobutamine ≥ 5 µg\u002Fkg\u002Fmin, or any other inotropic drug at any dose, or need for more than one volume expansion (20 ml\u002Fkg) in the 6 previous hours\n* Pulmonary hypertension requiring pharmacological treatment\n* Heart rate \\\u003C100 bpm\n* Hepatic impairment defined as alanine aminotransferase level \\> 2 x normal upper limit\n* Known contra-indications to dexmedetomidine: hypersensitivity, atrioventricular block, acute cerebrovascular event\n* Hypersensitivity to the active substance or to any of the excipients contained in the medicine","10 Weeks",{"count":50,"type":21},246,[52,53],"PHASE2","PHASE3","Despite the increasing use of non-invasive ventilation, a large majority of premature neonates still receive invasive ventilation during their NICU (neonatal intensive care unit) stay. Invasive ventilation is a unanimous source of discomfort and pain.\n\nAs opposed to the adult and pediatric population, routine use of opioids or midazolam is not recommended in ventilated neonates.\n\nAlthough opioids are the most frequently prescribed analgosedative drugs in ventilated premature neonates, their use is controversial because of the risk of respiratory depression - which can prolong invasive ventilation- and concerns on long-term neurodevelopment.\n\nDexmedetomidine, a selective alpha-2- adrenergic agonist routinely used in the adult ICU (intensive care unit), provides light sedation and some analgesia with no or little respiratory-depression effect. It also has neuroprotective properties after pediatric cardiac surgery and in neonatal animal models. Dexmedetomidine is thus a promising candidate drug in ventilated premature neonates that might reduce the duration of mechanical ventilation and preserve neurodevelopment in this vulnerable population.\n\nThe investigators hypothesize that the use of dexmedetomidine in ventilated premature neonates could decrease the need for opioids, facilitate extubation and thereby preserve long-term neurodevelopmental outcome.",[56,57,28,58,59],"Invasive Ventilation","Infant Pain","Infant Neurodevelopment","Neonatal Respiratory Failure",[61,62,63,64,65,66,67,68],"Neonatology","Invasive mechanical ventilation","Analgesia","Dexmedetomidine","Neurodevelopment","Opioids","Pain","Withdrawal syndrome","2026-03-20",{"date":71,"type":33},"2026-03-25",{"date":73,"type":21},"2026-06-01",{"date":75,"type":21},"2034-08-01",{"name":77,"class":40},"Centre Hospitalier Intercommunal Creteil",12]